C.M. Bidwell & Associates’s Vir Biotechnology VIR Stock Holding History

C.M. Bidwell & Associates’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-641	Closed	-$4.15K	–	497
2025 Q1	$4.15K	Buy	+641	New	+$5.7K	﹤0.01%	327
2024 Q3	–	Sell	-360	Closed	-$3.2K	–	547
2024 Q2	$3.2K	Sell	360 -41	-10%	-$393	﹤0.01%	373
2024 Q1	$4.06K	Buy	+401	New	+$4.08K	﹤0.01%	343
2023 Q3	–	Sell	-2,423	Closed	-$59.4K	–	603
2023 Q2	$59.4K	Buy	+2,423	New	+$60.8K	0.04%	277

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

C.M. Bidwell & Associates's VIR Position: Q2 2025 in Review

C.M. Bidwell & Associates sold out of Vir Biotechnology (VIR) in Q2 2025, closing a stake of 641 shares — an estimated $4.15K sold.

C.M. Bidwell & Associates first reported a position in VIR in Q2 2023 and held it in 4 quarters. The position peaked at $59.4K in Q2 2023. 213 funds tracked by Wall St. Rank hold VIR as of Q2 2025.

C.M. Bidwell & Associates reported no remaining Vir Biotechnology position as of Q2 2025 after selling out during the quarter.
C.M. Bidwell & Associates sold 641 Vir Biotechnology shares in Q2 2025, an estimated $4.15K.
C.M. Bidwell & Associates first reported a position in Vir Biotechnology in Q2 2023 and held it in 4 quarters.
C.M. Bidwell & Associates's Vir Biotechnology position peaked at $59.4K in Q2 2023.
213 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2025.

Based on C.M. Bidwell & Associates's 13F filing for Q2 2025, filed 14 Aug 2025.